Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.

MLA

Lakshminarayanan, Vani, et al. “Immune Recognition of Tumor-Associated Mucin MUC1 Is Achieved by a Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccine.” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 1, Jan. 2012, pp. 261–66. EBSCOhost, https://doi.org/10.1073/pnas.1115166109.

APA

Lakshminarayanan, V., Thompson, P., Wolfert, M. A., Buskas, T., Bradley, J. M., Pathangey, L. B., Madsen, C. S., Cohen, P. A., Gendler, S. J., & Boons, G.-J. (2012). Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proceedings of the National Academy of Sciences of the United States of America, 109(1), 261–266. https://doi.org/10.1073/pnas.1115166109

Chicago

Lakshminarayanan, Vani, Pamela Thompson, Margreet A Wolfert, Therese Buskas, Judy M Bradley, Latha B Pathangey, Cathy S Madsen, Peter A Cohen, Sandra J Gendler, and Geert-Jan Boons. 2012. “Immune Recognition of Tumor-Associated Mucin MUC1 Is Achieved by a Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccine.” Proceedings of the National Academy of Sciences of the United States of America 109 (1): 261–66. doi:10.1073/pnas.1115166109.